The options are for the freeze-dried version of Bavarian Nordic’s Jynneos, a formulation that allows easier stockpiling.

Exercised options total USD 143.6 million; Secures manufacturing and supply of freeze-dried JYNNEOS ® to the U.S. in 2026; COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/ ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US Government to add to vaccine reserves.

A recent study carried out at Charité Universitätsmedizin Berlin and published in The Lancet Infectious Diseases has shown that one dose of Bavarian Nordic’s Jynneos (smallpox and mpox vaccine ...

“Even in light of these promising data, we strongly recommend people receive two doses of Jynneos vaccine spaced out 28 days apart to ensure durable, lasting immune protection against monkeypox ...

Health officials are advising people at higher risk of mpox infection to consider being vaccinated with two doses of the JYNNEOS vaccine, which is available statewide. Laboratory testing of the ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in the US – is also safe and generates a strong antibody response in ...

Also, their recently FDA-approved freeze-dried Jynneos vaccine and EU/US-approved chikungunya vaccine launches are near-term growth catalysts. BVNKF’s 2025 outlook also suggests they still have ...

Mpox is a rare, but potentially serious, viral illness that typically involves flu-like symptoms, swollen lymph nodes and a rash that includes bumps that are filled with fluid before scabbing ...

Brazil's National Health Surveillance Agency (Anvisa) Thursday cleared the Health Ministry in separate but unanimous decisions to import and use the Jynneos / Imvanex vaccine and the drug ...

Exercised options total USD 143.6 million Secures manufacturing and supply of freeze-dried JYNNEOS ® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced ...

Bavarian Nordic said it was contracted by the U.S Biomedical Advanced Research and Development Authority to develop and supply the freeze-dried version of Jynneos for stockpiling.